Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Medpace Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Medpace Holdings's regulatory disclosures and financial reporting.
Medpace Holdings, Inc. director Robert O. Kraft exercised 33 restricted stock units into 33 shares of common stock on March 31, 2026. This reflects the first vesting installment from a November 28, 2025 grant of 130 restricted stock units scheduled to vest quarterly through December 31, 2026. Following the transaction, he holds 922 shares of common stock directly and 97 restricted stock units representing an equal number of potential future shares.
Medpace Holdings director Brian T. Carley exercised restricted stock units into common stock. On March 31, 2026, 36 restricted stock units converted into 36 shares at a stated price of $0.00 per share, bringing his direct common stock holdings to 32,789 shares and leaving 107 restricted stock units outstanding from a prior grant.
Medpace Holdings, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on director elections, auditor ratification, executive pay advisory votes and several governance changes. The meeting will be held online on May 15, 2026 via www.virtualshareholdermeeting.com/MEDP2026.
Stockholders of record on March 19, 2026, when 28,558,039 common shares were outstanding, may vote. The Board recommends voting for all five director nominees, for ratifying Deloitte & Touche LLP as auditor, for the Say‑on‑Pay resolution, for holding Say‑on‑Pay annually, for removing supermajority voting and for allowing stockholders to call special meetings, and against a similar overlapping stockholder proposal.
The proxy also reviews 2025 performance, including revenue of $2,530.2 million, GAAP net income of $451.1 million, diluted EPS of $15.28 and EBITDA of $557.7 million, all up from 2024, and explains how these results influenced executive compensation decisions.
The Vanguard Group filed an Amendment No. 7 to its Schedule 13G/A reporting 0 shares and 0% beneficial ownership of Medpace Holdings Inc. common stock following an internal realignment described in the filing.
The amendment explains certain Vanguard subsidiaries and business divisions will report ownership separately under SEC Release No. 34-39538; the filing is signed by Ashley Grim on 03/27/2026.
Medpace Holdings, Inc. executive vice president of operations Susan E. Burwig exercised employee stock options for 12,000 shares of common stock at an exercise price of $166.73 per share on March 18, 2026. The option had fully vested on October 27, 2025. Following the transactions, she owns 70,484 shares of common stock and 11,028 derivative securities directly.
Medpace Holdings, Inc. President Jesse J. Geiger exercised stock options and sold the resulting shares. He exercised options for 31,707 shares of common stock at an exercise price of $138.87 per share, then sold 31,707 shares in an open-market transaction at a weighted average price of $455.30 per share. Following these transactions, he holds 15,000 shares of Medpace common stock directly. The filing notes that the option vested in full on February 15, 2026 and that the sale price reflects multiple trades between $451.36 and $460.288 per share.
Medpace Holdings, Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders to be held at 9:00 a.m. Eastern Time on May 15, 2026. The Record Date for voting is March 19, 2026. The proxy materials describe seven core proposals, including the election of five directors, ratification of Deloitte & Touche LLP as the independent auditor, a non-binding Say-on-Pay advisory vote and a separate advisory vote on frequency, and two proposed amendments to the Certificate of Incorporation to remove supermajority voting and to remove the limitation on stockholders calling special meetings. The Board recommends voting FOR the director slate, auditor ratification, Say-on-Pay, and the certificate amendments, and AGAINST the stockholder proposal on special meetings. The meeting will be virtual only at www.virtualshareholdermeeting.com/MEDP2026, and stockholders are urged to vote by telephone, internet or by returning a proxy card.
Medpace Holdings, Inc. General Counsel & Corporate Secretary Stephen P. Ewald exercised employee stock options for 3,500 shares on February 17, 2026. This option exercise converted into 3,500 shares of common stock at $138.87 per share. Following the transactions, he directly held 16,843 shares of common stock and 19,849 derivative securities.
The option referenced in the filing vested in full on February 15, 2026.